LLLT reduced MI size, attenuated systolic dysfunction, and decreased myocardial mRNA expression of interleukin-1 beta and interleukin-6, as reported by Manchini et al. [41] in 2014, but did not show significant changes in vascular endothelial growth factor (VEGF) expression or capillaries' density [41]. The gene discussed is VEGFA; the disease is myocardial infarction.